全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Fatal Subacute Hepatic Failure in a Patient with AA-Type Amyloidosis: Case Report

DOI: 10.4061/2010/648089

Full-Text   Cite this paper   Add to My Lib

Abstract:

Although systemic amyloidosis of amyloid-associated protein (AA) type (secondary or reactive amyloidosis) frequently involves the liver, it rarely causes clinically apparent liver disease. Mild elevation of alkaline phosphatase and hepatomegaly are the most common biochemical and clinical findings, respectively. We report a case of systemic amyloidosis of AA type, which clinically presented as subacute hepatic failure and resulted in a fatal clinical course in a 69-year-old man. To the best of our knowledge, this is the fifth case of hepatic amyloidosis of AA type that clinically presented as fatal subacute hepatic failure, an unusual clinical presentation for hepatic involvement by systemic AA-type amyloid. 1. Introduction Hepatic involvement in systemic amyloidosis is common and occurs in myeloma-related (AL) (primary amyloidosis) and amyloid-associated (AA) (secondary or reactive) types of the disease. However significant clinical evidence of hepatic dysfunction is not common and the patients rarely exhibit clinical manifestations. These may include hepatomegaly, mild jaundice, and, rarely, severe cholestasis. Portal hypertension may complicate hepatic amyloidosis, and subcapsular hematoma and spontaneous rupture of liver were reported [1]. Subacute and acute, fulminant liver failures were previously reported, particularly in association with AL-type amyloidosis in the setting of myeloma [2]. Herein, we present an unusual case of AA-type amyloidosis with massive hepatic involvement and subacute liver failure—a clinical presentation rarely seen in secondary hepatic amyloidosis. 2. Case Report A previously healthy 69-year-old man presented with history of progressively increasing jaundice for six weeks and abdominal distension with swelling of the feet for four weeks. He also had symptoms of fatigue, poor appetite, and mild generalized itching. His past medical history was unremarkable, with no previous history of chronic liver disease. Upon physical examination, the patient had normal built exhibited severe jaundice, bilateral pitting lower-limb edema, left-sided moderate pleural effusion, short apical systolic murmur, and massive hepatomegaly, associated also with marked ascites without signs of overt congestive heart failure. Complete blood count and serum electrolytes were within normal limits. Laboratory studies showed blood urea 3.9?mmol/l (normal range 3–9.2), creatinine 64 mol/l (45–110), total bilirubin of 196? mol/l (3.4–20.5), serum albumin 24?g/l (35–50), INR 3.2, alkaline phosphatase 256 IU/l (40–150), γ-glutamyltransferase 136 (2–30),

References

[1]  L. Bujanda, A. Beguiristain, F. Alberdi, et al., “Spontaneous rupture of the liver in amyloidosis,” American Journal of Gastroenterology, vol. 92, no. 8, pp. 1385–1386, 1997.
[2]  N. C. Ales, J. T. Daniels, E. R. Frizell, J. M. Koff, K. J. Kaplan, and G. W. Wortmann, “Multiple myeloma-associated amyloidosis manifesting as fulminant hepatic failure,” Southern Medical Journal, vol. 94, no. 10, pp. 1036–1038, 2001.
[3]  E. C. Ebert and M. Nagar, “Gastrointestinal manifestations of amyloidosis,” American Journal of Gastroenterology, vol. 103, no. 3, pp. 776–787, 2008.
[4]  T. J. Cross, J. A. Wendon, A. Quaglia, J. R. Salisbury, M. A. Heneghan, and P. M. Harrison, “Myeloma associated amyloidosis presenting as subacute liver failure,” Postgraduate Medical Journal, vol. 82, no. 969, p. e13, 2006.
[5]  T. Yamamoto, N. Maeda, and H. Kawasaki, “Hepatic failure in a case of multiple myeloma-associated amyloidosis ( -AL),” Journal of Gastroenterology, vol. 33, pp. 926–927, 1998.
[6]  H. J. Jeong, E. K. Hahn, E. Kim, and C. I. Park, “Hepatic amyloidosis: two cases report,” Journal of Korean Medical Science, vol. 3, no. 4, pp. 151–155, 1988.
[7]  K. H. Kilburn, “Secondary amyloidosis and hepatic failure in Hodgkin's disease,” The American Journal of Medicine, vol. 24, no. 4, pp. 654–658, 1958.
[8]  S. K?klü, B. ?demi, C. Cengiz, O. Yüksel, O. üsküdar, and N. Turhan, “Fulminant hepatic failure due to secondary amyloidosis,” Digestive and Liver Disease, vol. 38, no. 3, pp. 208–210, 2006.
[9]  J. Lloreta, C. Vadell, X. Fabregat, and S. Serrano, “Fibrolamellar hepatic tumor with neurosecretory features and systemic deposition of AA amyloid,” Ultrastructural Pathology, vol. 18, no. 1-2, pp. 287–292, 1994.
[10]  L. B. Lovat, M. R. Persey, S. Madhoo, M. B. Pepys, and P. N. Hawkins, “The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients,” Gut, vol. 42, no. 5, pp. 727–734, 1998.
[11]  N. Agaram, J. Shia, D. S. Klimstra, et al., “Globular hepatic amyloid: a diagnostic peculiarity that bears clinical significance,” Human Pathology, vol. 36, no. 7, pp. 845–849, 2005.
[12]  H. R. Makhlouf and Z. D. Goodman, “Globular hepatic amyloid: an early stage in the pathway of amyloid formation: a study of 20 new cases,” American Journal of Surgical Pathology, vol. 31, no. 10, pp. 1615–1621, 2007.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133